4. Jones MH, Virtanen C, Honjoh D et al Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004; 363: 775–781

high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004; 363: 775–781. 5. Asamura H, Kameya T, Matsuno Y et al Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 2006; 24: 70–76. 6. Battafarano RJ, Fernandez FG, Ritter J et al Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg 2005; 130: 166–172. 7. Fernandez FG, Battafarano RJ. Large-cell neuroendocrine carcinoma of the lung: an aggressive neuroendocrine lung cancer. Semin Thorac Cardiovasc Surg 2006; 18: 206–210. 8. Gollard R, Jhatakia S, Elliott M et al Large cell/neuroendocrine carcinoma. Lung Cancer 2010; 69: 13–18. 9. Sun JM, Ahn MJ, Ahn JS et al Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? Lung Cancer 2012; 77: 365–370. 10. Yamazaki S, Sekine I, Matsuno Y et al Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer 2005; 49: 217–223. 11. Mazieres J, Daste G, Molinier L et al Large cell neuroendocrine carcinoma of the lung: pathological study and clinical outcome of 18 resected cases. Lung Cancer 2002; 37: 287–292. 12. Rossi G, Mengoli MC, Cavazza A. Pulmonary large cell neuroendocrine carcinoma: a true high-grade neuroendocrine tumor needing prospective therapeutic data. J Thorac Oncol 2011; 6: 1775. 13. Kozuki T, Fujimoto N, Ueoka H et al Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma. J Cancer Res Clin Oncol 2005; 131: 147–151. 14. Fujiwara Y, Sekine I, Tsuta K et al Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung. Jpn J Clin Oncol 2007; 37: 482–486. 15. Igawa S, Watanabe R, Ito I et al Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. Lung Cancer 2010; 68: 438–445. 16. Shimada Y, Niho S, Ishii G et al Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens. Lung Cancer 2012; 75: 368–373. 17. Noda K, Nishiwaki Y, Kawahara M et al Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346: 85–91. 18. Hanna N, Bunn PA, Jr, Langer C et al Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006; 24: 2038–2043. 19. Varlotto JM, Medford-Davis LN, Recht A et al Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas? J Thorac Oncol 2011; 6: 1050–1058. 20. Rossi G, Cavazza A, Marchioni A et al Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFR alpha. PDGFR-beta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 2005; 23: 8774–8785.